Modified Vaccinia Ankara virus variant

Details Modified Vaccinia Ankara virus variant Modified Vaccinia Ankara virus variant

2011-05-10

2011-05-10

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S184100, C424S199100, C424S204100, C424S201100, C424S281100, C435S235100, C435S236000, C435S320100

Reexamination Certificate

active

07939086

ABSTRACT:
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.

REFERENCES:
patent: 5155020 (1992-10-01), Paoletti et al.
patent: 5185146 (1993-02-01), Altenberger et al.
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 6663871 (2003-12-01), McMichael et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 6976752 (2005-12-01), Parish et al.
patent: 7097842 (2006-08-01), Suter et al.
patent: 7189536 (2007-03-01), Chaplin et al.
patent: 7335364 (2008-02-01), Chaplin et al.
patent: 7384644 (2008-06-01), Chaplin et al.
patent: 7445924 (2008-11-01), Chaplin et al.
patent: 7459270 (2008-12-01), Chaplin et al.
patent: 2002/0106798 (2002-08-01), Robinson et al.
patent: 2003/0138454 (2003-07-01), Hill et al.
patent: 2004/0131594 (2004-07-01), McMichael et al.
patent: 2005/0214323 (2005-09-01), Chaplin et al.
patent: 2006/0029619 (2006-02-01), Howley et al.
patent: 2006/0127984 (2006-06-01), Ackermann et al.
patent: 2006/0159699 (2006-07-01), Howley et al.
patent: 2006/0165727 (2006-07-01), Howley et al.
patent: 2006/0280758 (2006-12-01), Chaplin et al.
patent: 2009/0169579 (2009-07-01), Chaplin et al.
patent: 0836648 (1998-04-01), None
patent: 321679 (2003-05-01), None
patent: 1312678 (2003-05-01), None
patent: 1335987 (2005-12-01), None
patent: WO95/22978 (1995-08-01), None
patent: 96/03144 (1996-02-01), None
patent: WO97/02355 (1997-01-01), None
patent: WO97/31119 (1997-08-01), None
patent: WO98/13500 (1998-04-01), None
patent: WO98/56919 (1998-12-01), None
patent: WO99/07869 (1999-02-01), None
patent: WO00/28016 (2000-05-01), None
patent: WO00/29428 (2000-05-01), None
patent: WO01/69920 (2001-09-01), None
patent: WO02/24224 (2002-03-01), None
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmacuetical Compositions Based Thereon, Investigation No. 337-TA-550, Commission Opinion On behalf of the Office of the Secretary, Document ID: 270867, United States International Trade Commission, Washington, D.C., Mar. 6, 2007.
Bowie et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, 1990, Science, vol. 247, No. 4948, pp. 1306-1310.
Drexler, et al., J. Gen. Virol. (1998) 79:347-352.
International Preliminary Examination Report, dated Jan. 11, 2006, four (4) pages.
Tartaglia, et al. “NYVAC: a highly attenuated strain of vaccinia virus”—Virology 1992, vol. 188, pp. 217-232.
Kovarik, et al. “Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC (K1L) viral vector” Virology Jun. 20, 2001, vol. 285, pp. 12-20.
Kazanji. et al. “Immunogenicity and protective efficacy of recombinant human T-cell leukaemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus)” Journal of Virology, Jul. 2001, vol. 75(13), pp. 5939-5948.
U.S. International Trade Commission, Inv. No. 337-TA-550, Order No. 10: Denying Respondent's Motion to Terminate and Entry of Consent Order, Nov. 30, 2005, pp. 1-8.
Inv. No. 337-TA-550, Complainant Bavarian Nordic's Motion for Summary Determination of Infringement of the '893 Patent, Mar. 20, 2005, pp. 1-15.
U.S. International Trade Commission, Inv. No. 337-TA-550, Complainant's Petition for Review of the Final Initial Determination, Sep. 18, 2006, pp. 1-52.
U.S. International Trade Commission, Inv. No. 337-TA-550, Order No. 16: Granting Complainant's Motion to Declassify Confidential Information, Feb. 15, 2006, pp. 1-8.
U.S. International Trade Commission, Inv. No. 337-TA-550, Bavarian Nordic's Complaint Under Section 337 of the Tariff Act of 1930, Aug. 19, 2005, pp. 1-30.
Federal Register, vol. 70, No. 184, Sep. 23, 2005, pp. 55918-55919.
U.S. International Trade Commission, Inv. No. 337-TA-550, Memorandum in Opposition to Respondent's Motion to Terminate, Nov. 28, 2005, pp. 1-17.
U.S. International Trade Commission, Inv, No. 337-TA-550, Memorandum in Support of Respondent's Motion for Summary Determination, Mar. 30, 2005, pp. 1-48.
U.S. International Trade Commission, Inv. No. 337-TA.:550, Appendix to Memorandum in Support of Respondent's Motion for Summary Determination, vol. 1 of 3, Oct. 31, 2005, pp. 1-64.
U.S. International Trade Commission, Inv. No. 337-TA-550, Appendix to Memorandum in Support of Respondent's Motion for Summary Determination, vol. 2 of 3, Dec. 1, 2005, pp. 1-45.
U.S. International Trade Commission, Inv. No. 337-TA-550, Notice of Investigation, Sep. 19, 2005.
U.S. International Trade Commission, Inv. No. 337-TA-550, Respondent's Opposition to Complainant's Motion to Declassify Confidential Information, Feb. 13, 2006, pp. 1-9.
U.S. International Trade Commission, Inv. No. 337-TA-550, Motion for Leave to File Reply in Support of Respondent's Motion for Summary Determination (pp. 1-2), Respondent's Certification Pursuant to Ground Rule 3.2 (p. 1), and Reply in Support of Respondent's Motion for Summary Determination, Apr. 5, 2005 (pp. 1-3), Apr. 5, 2006.
U.S. International Trade Commission, Inv. No. 337-TA-550, Respondent's Notice of Prior Art, Feb. 3, 2006, pp. 1-8.
U.S. International Trade Commission, Inv. No. 337-TA-550, Response of Acambis plc Under Section 337 of the Tariff Act of 1930 and Notice of Investigation, Oct. 21, 2005, pp. 1-24.
U.S. International Trade Commission, Inv. No. 337-TA-550, Commission Investigative Staff's Response to the Private Parties' Motions in Limine, May 3, 2006, pp. 1-5.
U.S. International Trade Commission, Inv. No. 337-TA-550, Commission Investigative Staff's Notice of Prior Art, Feb. 3, 2006.
U.S. International Trade Commission, Inv. No. 337-TA-550, Consent Order Stipulation, Nov. 2, 2005, pp. 1-4.
U.S. International Trade Commission, Inv. No. 337-TA-550, Consent Order Stipulation (pp. 1-4) with Commission Opinion of Feb. 21, 2007pp. 1-39.
U.S. International Trade Commission, Inv. No. 337-TA-550, Office of Unfair Import Investigation's Response to Commission Notice of January 1912007 Jan. 26, 2007, pp. 1-8.
U.S. International Trade Commission, Inv. No. 337-TA-550, Office of Unfair Import Investigations' Combined Response to Bavarian Nordic and Acambis PLC's Responses to Questions Posed by the Commission, Dec. 22, 2006, pp. 1-23.
U.S. International Trade Commission, Inv. No. 337-TA-550, Office of Unfair Import Investigations' Response to Questions Posed in the Commission's Order of Nov. 22, 2006 and Briefing on the Issues of Remedy, Public Interest, and Bonding, Dec. 12, 2006, 1-30.
U.S. International Trade Commission, Inv. No. 337-TA-550, Initial Determination on Violation of Section 337 and Recommended Determination on Remedy and Bonding, Sep. 6, 2006.
U.S. International Trade Commission, Inv. No. 337-TA-550, Respondent's Post-Hearing Brief, Aug. 15, 2006, pp. 1-80.
U.S. International Trade Commission, Inv. No. 337-TA-550, Complainant's Response to Respondent's Petition for Commission Review of the Initial Determination, Sep. 25, 2006, pp. 1-20.
U.S. International Trade Commission, Inv. No. 337-TA-550, Complainant's Response to the OUII Petition for Commission Review of the Initial Determination, Sep. 25, 2006, pp. 1-11.
U.S. International Trade Commission, Inv. No. 337-TA-550, Complainant Bavarian Nordic's Opening Written Submission to the Commission on the Issues Under Review Associated with the Final Initial Determination and Order No. 10, January 2412007, pp. 1-72.
U.S. International Trade Commission, Inv. No. 33

Affiliated with

Also associated with

Rating

Modified Vaccinia Ankara virus variant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified Vaccinia Ankara virus variant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified Vaccinia Ankara virus variant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2676378